SINGAPORE, May 16, 2013 /PRNewswire/ -- Biosensors International Group, Ltd. ("Biosensors" or the "Company", Bloomberg: BIG SP; Reuters: BIOS.SI; SGX: B20), a developer, manufacturer and marketer of innovative medical devices, announced on May 13, 2013 that it has entered into an agreement to acquire substantially all assets of Spectrum Dynamics, a leader in advanced functional assessment technologies, including those used to evaluate patients for cardiac interventions, subject to the fulfillment of certain conditions.
Founded in 2004, Spectrum Dynamics is a privately held medical imaging and clinical applications company that has developed innovative technology providing high-speed, high-resolution functional 3D images to help physicians determine the most appropriate treatment for their patients.
Used by leading medical centers around the world, Spectrum Dynamics' revolutionary D-SPECT Cardiac Imaging System lays the foundation for its next-generation cardiac clinical protocols that will provide new diagnostic information and treatment strategies to interventional cardiologists.
Spectrum Dynamics has more than 70 issued and pending patents. It is ISO-certified and its products have been approved for sale in major markets including the US, Japan, Europe and Canada. Additional approvals in other key markets are pending.
"We are very excited about becoming a part of Biosensors' growing family. The synergy created as a result of this deal will provide us with meaningful resources to better realize the potential of our business," said Prof. Shlomo Ben-Haim , Co-Founder and Chairman of Spectrum Dynamics. "The ability to accurately detect and diagnose reversible ischemia prior to catheterization has become a critical is
|SOURCE Biosensors International Group, Ltd.|
Copyright©2012 PR Newswire.
All rights reserved